The Pharma Data
NOVEMBER 23, 2021
The study compared the two groups’ plasma CMV DNA concentration levels at the end of the study’s eighth week, with efficacy defined as having a level below what is measurable. Livtencity may reduce the antiviral activity of ganciclovir and valganciclovir, so coadministration with these drugs is not recommended. Source link: [link].
The Pharma Data
APRIL 20, 2022
Food and Drug Administration is warning the public of the risk of false results, inappropriate use and inappropriate interpretation of results with non-invasive prenatal screening (NIPS) tests, also called cell-free DNA tests or non-invasive prenatal tests (NIPT). Most LDTs, including NIPS tests, are offered without review by the FDA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 7, 2022
Animals with Intentional Genomic Alterations Intentional Genomic Alterations in Animals: Enforcement Discretion Draft Guidance for Industry: Regulation of Intentionally Altered Genomic DNA in Animals Risk Assessment Summary: PRLR-SLICK Cattle. ###. Related Information. The FDA, an agency within the U.S. Source link: [link].
Pfizer
AUGUST 15, 2022
In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Herbal Products: St.
XTalks
FEBRUARY 26, 2021
Carver’s biggest successes came from peanuts, as he developed more than 300 food, industrial and commercial products from the nut, including milk, cooking and salad oils, Worcestershire sauce, paper, cosmetics, soaps and wood stains. Since then, the cells have been used to test sensitivity to various products ranging from glue to cosmetics.
The Pharma Data
APRIL 30, 2021
Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie.
Pfizer
DECEMBER 13, 2022
In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Herbal Products: St.
Expert insights. Personalized for you.
52 
Let's personalize your content